Ozempic FAQ: Approved Uses, Costs, Medicare, Pills and Side Effects

Ozempic is the Novo Nordisk brand of semaglutide, a GLP-1 receptor agonist that was first approved in the United States in 2017 ^[1]. It comes as a once-weekly injection and, since 2026, as a once-daily pill, and it is FDA-approved only for adults with type 2 diabetes: to improve blood sugar control, to lower the risk of major cardiovascular events in people with established cardiovascular disease, and (injection only) to lower the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in people with chronic kidney disease ^[1][7]. It is not approved for weight loss, and insurance coverage for weight-loss use is unlikely ^[2][4][5].

Cost is the biggest practical issue for most people. The list price is $1,027.51 per pen or 30-tablet bottle, the same across doses, but most people do not pay list ^[3][4]. Novo Nordisk’s self-pay prices run $349 a month for most injection doses and $499 for the 2 mg dose, with tablet prices from $149 to $299 ^[3]. For Medicare, a CMS-negotiated price of $274 per 30-day supply takes effect January 1, 2027 ^[10].

What is Ozempic approved to treat?

The injection is approved for three uses in adults with type 2 diabetes: improving glycemic control alongside diet and exercise; reducing the risk of major adverse cardiovascular events in people with established cardiovascular disease; and reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in people with chronic kidney disease ^[1].

The tablets carry the first two of those indications, glycemic control and cardiovascular risk reduction in high-risk type 2 diabetes, but the kidney indication is injection only ^[7][2].

Is Ozempic approved for weight loss?

No. Ozempic is not FDA-approved for weight loss, and insurance plans typically do not cover it for that purpose ^[2][4][5]. The same active ingredient is sold as Wegovy for weight management, as an injection at 1.7 mg or 2.4 mg and as 25 mg tablets ^[9][2]. Wegovy’s labeling states it should not be used with other semaglutide-containing products ^[9]. Prescribers do sometimes use Ozempic off-label for weight management ^[4].

In the 30-week SUSTAIN 1 trial, people taking semaglutide lost 3.5 kg (7.7 lb) more than placebo at the 1 mg dose and 2.6 kg (5.7 lb) more at 0.5 mg, and 73% of those on 0.5 mg reached an A1C of 7% or less ^[2].

What is the Ozempic pill, and how is it taken?

The pill is the drug formerly sold as Rybelsus. The FDA approved renaming Rybelsus (formulation R2) to Ozempic tablets under NDA 213051/S-030, with the approval letter signed January 30, 2026 ^[6]. HCPLive reported Novo Nordisk’s announcement of the rebrand on February 4, 2026, noting it is the same active ingredient, not a new molecule, and that Novo said US availability would come in Q2 2026 ^[8].

Ozempic tablets come in 1.5 mg, 4 mg and 9 mg strengths, while Rybelsus tablets come in 3 mg, 7 mg and 14 mg, and the label states they are not substitutable on a mg-to-mg basis ^[7]. The label directs patients to take the tablet once daily on an empty stomach in the morning with up to 4 ounces of water only, to swallow it whole, and to wait at least 30 minutes before food, drink or other oral medications ^[7]. Even though it is taken daily, its half-life is about one week ^[8].

How much does Ozempic cost without insurance?

The list price is $1,027.51 per pen or 30-tablet bottle, the same for every dose, and most people do not pay it ^[3][4]. Retail cash prices without a discount average about $1,200 a month according to GoodRx, and SingleCare reports about $1,396 per pen; these are averages that vary by pharmacy, not list prices ^[4][5].

Novo Nordisk’s self-pay prices, supplied through ozempic.com, NovoCare Pharmacy and other participating organizations, are lower ^[3]:

Form and dose	Self-pay price per month
Injection 0.25 or 0.5 mg, first two fills (new self-pay patients)	$199 [3][20]
Injection 0.25, 0.5 or 1 mg	$349 [3]
Injection 2 mg	$499 [3]
Tablets 1.5 mg	$149 [3]
Tablets 4 mg	$199 [3]
Tablets 9 mg	$299 [3]

The $199 introductory offer applies to new self-pay patients for fills between November 17, 2025 and December 31, 2026 ^[3][20]. TrumpRx.gov lists the Ozempic pen self-pay offer; the coupon is shown at the pharmacy, is for self-pay only, is not reimbursable by insurance and does not count toward a deductible ^[20].

What savings programs exist for insured patients?

With commercial insurance that covers Ozempic, a manufacturer copay card can bring the cost to as little as $25 for a 1-, 2- or 3-month fill, with maximum savings of $100 per month ^[4][3]. The card requires commercial insurance that covers Ozempic, excludes Medicare and Medicaid enrollees, and is limited to FDA-approved uses ^[4][3].

Novo Nordisk also runs a patient assistance program for people who are uninsured or on Medicare, with income limits and US citizenship or legal residency required; it covers pens only, not pills ^[4]. Prior authorization is commonly required before insurance will pay, and the forms typically ask for a diabetes diagnosis, recent A1C and prior medications ^[5].

Does Medicare cover Ozempic?

Yes. The semaglutide group (Ozempic, Rybelsus, Wegovy) is a drug covered under Medicare Part D, and 2,282,000 Part D enrollees used it in 2024, accounting for $15.16 billion in Part D gross covered prescription drug costs ^[10]. What an individual pays varies by Part D plan, and Medicaid coverage varies by state ^[5]. The manufacturer copay card is not available to Medicare or Medicaid enrollees ^[4].

People with Medicare and limited income and resources may qualify for Part D Extra Help with prescription costs ^[4].

Separately, CMS is running a short-term demonstration called the Medicare GLP-1 Bridge from July 1, 2026 through December 31, 2027, which provides eligible Part D beneficiaries access to certain GLP-1 drugs ^[11]. It operates outside the Part D benefit, with a $50 copay; the Part D deductible does not apply, the copay does not count toward out-of-pocket totals, and there is no low-income subsidy ^[11]. Beneficiaries can check eligibility at Medicare.gov or by calling 1-800-MEDICARE ^[11].

What prices change in 2027?

Two changes take effect January 1, 2027. Novo Nordisk announced on February 24, 2026 that the list price of Ozempic will drop to $675 a month, about a 35% cut, with self-pay prices unaffected ^[9]. And under the Medicare Drug Price Negotiation Program, CMS negotiated a price of $274 per 30-day supply for the Ozempic/Rybelsus/Wegovy group, a 71% discount from the $959 list price for a 30-day supply in 2024 ^[10].

CMS lists the negotiated price per package as $276.78 for the Ozempic 4 mg/3 mL pen, $276.78 for Rybelsus 7 mg 30 tablets, and $385.63 for Wegovy 2.4 mg 4 pens ^[10]. The $274 figure is a Medicare negotiated price, not a cash or list price. In 2027, Medicare coinsurance is calculated on the negotiated price rather than list ^[5].

How is the injection dosed, and what if a dose is missed?

The label’s schedule starts at 0.25 mg once weekly for 4 weeks to reduce gastrointestinal reactions, then moves to 0.5 mg; maintenance doses are 0.5, 1 or 2 mg once weekly, with each increase coming after at least 4 weeks on the prior dose ^[1]. Dose decisions belong to a prescriber.

The injection is given once weekly on the same day, at any time of day, with or without meals, into the abdomen, thigh or upper arm ^[1]. The day of the week can be changed as long as at least 2 days (over 48 hours) separate two doses, and a pen should never be shared between patients, even with a new needle ^[1].

If a dose is missed, the label says to take it as soon as possible within 5 days; if more than 5 days have passed, skip it and take the next scheduled dose ^[1]. The label also says to stop at least 2 months before a planned pregnancy, and to tell healthcare providers before surgery or sedation because of the aspiration risk ^[1].

What are the side effects and warning signs?

The most common side effects, reported in 5% or more of patients, are nausea, vomiting, diarrhea, abdominal pain and constipation, along with decreased appetite ^[1][2]. Drugs.com lists warning signs that call for medical attention, including pancreatitis (severe upper stomach pain spreading to the back) and gallbladder problems (upper stomach pain, fever, clay-colored stools, jaundice) ^[2].

Other labeled risks include acute kidney injury from fluid loss, low blood sugar when taken with insulin or a sulfonylurea, diabetic retinopathy complications, and anaphylaxis and angioedema ^[1]. The boxed warning states that semaglutide causes thyroid C-cell tumors in rodents and that human relevance has not been determined; the drug is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2 ^[1].

“Ozempic face” is a coined term for facial volume loss with semaglutide therapy; a systematic review of 23 articles found the concept discussed in the plastic surgery literature but noted the review was limited by study biases ^[18].

What did the heart and kidney trials show?

The FLOW trial enrolled 3,533 people with type 2 diabetes and chronic kidney disease, randomly assigned to 1 mg semaglutide weekly or placebo, and was stopped early at a prespecified interim analysis after a median follow-up of 3.4 years ^[12]. Major kidney disease events were 24% lower with semaglutide (hazard ratio 0.76), death from cardiovascular causes was lower (hazard ratio 0.71), and death from any cause was 20% lower ^[12].

The SELECT trial enrolled 17,604 people with preexisting cardiovascular disease and overweight or obesity but no diabetes, testing 2.4 mg weekly semaglutide, which is the Wegovy dose, not an Ozempic dose ^[13]. A primary cardiovascular event occurred in 6.5% of the semaglutide group versus 8.0% of the placebo group (hazard ratio 0.80) ^[13].

Is there a generic, and what about compounded semaglutide?

There is no generic on the market yet. Apotex, with Orbicular, received the first FDA tentative approval for a generic semaglutide injection on April 10, 2026, but the product must wait for final approval eligibility before launch ^[17].

The FDA determined the semaglutide injection shortage was resolved on February 21, 2025, and its enforcement discretion for compounders ended after an April 24, 2025 court ruling for 503A pharmacies and on May 22, 2025 for 503B outsourcing facilities ^[14]. As of April 1, 2026, semaglutide does not appear on the 503B bulks list or on FDA’s drug shortage list ^[14]. Compounded drugs do not undergo the premarket review generics receive, and the FDA has issued warning letters to 30 telehealth companies over misleading compounded semaglutide claims ^[17].

Counterfeit Ozempic 1 mg pens have been seized in the legitimate US supply chain, in lots NAR0074 (2023), PAR0362 (2025) and PAR1229 (December 2025, identifiable by the placement of the EXP/LOT text on the pen label) ^[15]. The FDA advises obtaining Ozempic only with a prescription from a state-licensed pharmacy ^[15].

What is happening with Ozempic lawsuits?

As of September 2026, there were 4,022 personal injury lawsuits involving gastroparesis, ileus and intestinal obstruction in MDL 3094 in the Eastern District of Pennsylvania, before Judge Karen S. Marston ^[16]. A separate multidistrict litigation over vision loss (NAION) is before the same judge, with more than 200 federal vision loss suits filed ^[16].

No global settlement had been reached as of September 2026, and the summary judgment process was ongoing in August 2026 ^[16]. The claims are failure-to-warn allegations and have not been decided ^[16]. Drugwatch, one source of this litigation reporting, is run by a law firm, The Wilson Firm ^[16].

Sources

1. National Library of Medicine DailyMed. OZEMPIC (semaglutide) injection, solution.
2. Drugs.com. Ozempic: Uses, Dosage, Side Effects, Warnings. August 14, 2026.
3. Drugs.com. How much does Ozempic cost with or without insurance? May 8, 2026.
4. GoodRx. How Much Ozempic Costs Without Insurance — and 6 Ways to Save.
5. SingleCare. Ozempic cost without insurance. September 2026.
6. US Food and Drug Administration. Supplement approval letter: Ozempic (semaglutide) tablets and Rybelsus (semaglutide) tablets.
7. US Food and Drug Administration. OZEMPIC (semaglutide) tablets prescribing information.
8. HCPLive. Novo Nordisk Rebrands Rybelsus as Ozempic to Increase Patient Awareness. February 17, 2026.
9. PR Newswire. Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic, and Rybelsus (semaglutide medicines), building on continued efforts to expand access.
10. Centers for Medicare & Medicaid Services. Fact Sheet: Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027. June 2023.
11. Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge.
12. PubMed. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
13. PubMed. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
14. US Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.
15. US Food and Drug Administration. FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain.
16. Drugwatch. Ozempic Lawsuit: September 2026 Blindness and Gastroparesis Claims.
17. Drug Topics. FDA Tentatively Approves Generic Version of Semaglutide. April 10, 2026.
18. PubMed Central. “Ozempic Face” in Plastic Surgery: A Systematic Review of the Literature on GLP-1 Receptor Agonist Mediated Weight Loss and Analysis of Public Perceptions.
19. Mayo Clinic. Semaglutide (subcutaneous route) - Side effects & dosage.
20. TrumpRx. Ozempic Pen.